Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

The primary objective is to compare the progression-free survival (PFS) between aromatase inhibitors interruption and aromatase inhibitors maintenance strategies in patients with a locally advanced or metastatic Low Grade Endometrial Stromal Sarcoma (LGESS).

Trial Details

NCT ID
NCT03624244
Phase
PHASE2
Sponsor
Centre Leon Berard
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • Aromatase Inhibitors
Locations (sample)
  • Besançon, France|47.24878,6.01815
  • Bordeaux, France|44.84124,-0.58046
  • Caen, France|49.18585,-0.35912
  • Clermont-Ferrand, France|45.77969,3.08682
  • Lille, France|50.63391,3.05512

Key Eligibility Criteria

  • Age≥18 years;
  • Histological confirmation of low grade ESS;
  • Locally advanced or metastatic disease at diagnosis or patient experiencing a tumor effraction during hysterectomy;
  • Treatment with aromatase inhibitors (Anastrozole or Exemestane or Letrozole ) initiated either: for at least 24 months (in patients with no residua…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →